Compare Crown Castle International Corp (CCI) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs ClearPoint Neuro Inc — how do they compare? Crown Castle International Corp trades at $79.21 (market cap $34.50B), while ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M). The key difference: Crown Castle International Corp is far larger — about 72.1× ClearPoint Neuro Inc's market cap, and Crown Castle International Corp pays a 5.38% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CCI | CLPT | |
|---|---|---|
Market Cap | $34.50B | $478.63M |
Sector | Real Estate | Health |
52-Week High | $113.91 | $29.60 |
52-Week Low | $74.92 | $8.66 |
Enterprise Value | $64.33B | $506.63M |
Dividend Yield | 5.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $79.84, up 0.23% on the day, with a bearish technical signal from moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates, but maintains strong profitability with a 73.82% gross margin. Recent news highlights its pure-play U.S. tower focus and upcoming Q2 2026 earnings call on July 22, 2026.
CCI presents a turnaround opportunity with analyst consensus targeting $97.33, implying 22% upside, but faces risks from high debt levels and volatile earnings. The stock's negative equity and bearish technicals warrant caution despite attractive dividend yield and cost reduction initiatives.
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
